LINK Medical AS og Melanor inngår samarbeidsavtale
LINK Medial AS og Melanor har inngått samarbeidsavtale som gir medlemmer tilgang til nødvendig kompetanse og rådgiving på gunstige vilkår i prosessen mot registering av medisinsk utstyr.
Latest news
LINK Medical contracted by Hemanext to run a study to assess the Hemanext ONE® Red Blood Cell (RBC) Processing and Storage System
Hemanext, inc. appoints LINK Medical Research to run a study to assess the Hemanext ONE® Red Blood Cell (RBC) Processing and Storage System. The study will include patients that receive transfusions of hypoxic RBC units processed with Hemanext ONE, with the purpose of evaluating the safety and efficacy of hypoxic red blood cells processed with the Hemanext ONE system.
LIPIGON CHOOSES LINK MEDICAL AS THEIR CRO
Lipigon Pharmaceuticals AB have chosen LINK Medical, a Nordic contract research organization (CRO) for the planning and design of their clinical phase II study with Lipisense. The study aims to study safety and treatment effects in patients with severely elevated levels of the blood fat triglyceride.
Positive Results for AlzeCure’s Phase IIa clinical study in neuropathic pain with the non-opioid ACD440
LINK Medical, and AlzeCure® Pharma AB (publ) (FN STO: ALZCUR) announce the positive data results from the Phase IIa clinical study with the non-opioid drug candidate ACD440, which is developed against peripheral neuropathic pain
Pharm Assist is now part of LINK Medical, making the Regulatory team one of the largest and unique in Northern Europe
Pharm Assist is now part of LINK Medical, making the Regulatory team one of the largest and unique in Northern Europe
The patient recruitment milestone has been reached for AlzeCure's Phase II clinical trial in neuropathic pain with non-opioid ACD440
LINK Medical, the Northern European clinical research organization (CRO), and AlzeCureÒ Pharma AB (publ) (FN STO: ALZCUR), announced today that the last patient has been enrolled in the phase II clinical trial for neuropathic pain treated with the non-opioid ACD440.
New CEO at LINK Medical, the Northern European CRO
The LINK Medical Board is pleased to announce the appointment of Sissel Lønning Andresen as the new CEO of LINK Medical one of the leading Northern European CROs. Sissel will assume the company's CEO position as of January 1st, 2023.
Social media
Contacts
